Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A 24-week, interferon-free regimen pairing two drugs from Bristol-Myers Squibb--60 milligrams (mg) of daclatasvir, a once-daily NS5a...
A 12-week, interferon-free combination of two experimental, once-daily drugs cured nine of 11 (82 percent) first-time treatment takers
A 12-week regimen of ribavirin plus two experimental drugs kept HCV levels undetectable for 12 weeks after completing treatment in over 90%
Early follow-up data continues to show promise as a cornerstone of interferon-free treatment
All-oral treatment kept undetectable for four weeks after treatment in 100% of people genotype 1 infection and 91% of people with 2 or 3
A novel version of interferon, pegylated interferon lambda-1a (peg-IFN-lambda), combined with ribavirin cured up to three-quarters of...
Ninety percent of people with genotype 1 hepatitis C virus (HCV) starting therapy for the first time show a clear sign of being cured
Up to 80 percent of people with genotype 1 hepatitis C virus (HCV) who didn’t respond successfully to earlier therapy were cured
Additional data from a Merck-sponsored clinical trial help clarify the efficacy of Victrelis combined with interferon and ribavirin
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.